Is BDRX or BGM more undervalued in 2026?

CirclFi compares Biodexa Pharmaceuticals plc (BDRX) and BGM Group Ltd. (BGM) using 13 institutional-grade valuation models. BDRX has a Quality of Company score of 1.7/10 while BGM scores 2.2/10.

Which is a better buy — BDRX or BGM?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do BDRX and BGM valuations compare?

BDRX at $3.47 and BGM at $0.32 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

BDRX vs BGM Valuation Comparison 2026 — Intrinsic Value Analysis

BDRX

Pharmaceutical Preparations

Biodexa Pharmaceuticals plc

Quality

1.7

out of 10

Value Trap

—

Price

$3.47

Last close

Models

5/13

Active

BGM

Pharmaceutical Preparations

BGM Group Ltd.

Quality

2.2

out of 10

Value Trap

—

Price

$0.32

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	BDRX Fair Value	BDRX Upside	BGM Fair Value	BGM Upside
Bayesian DCF	Intrinsic	$0.85	-75.6%	$0.06	-81.1%
Earnings Power Value	Intrinsic	—	—	$0.02	-92.1%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$16.83	+384.9%	$0.93	+192.1%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for BDRX vs BGM — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BDRX vs BGM — Which Stock Is More Undervalued?

BGM scores higher with a 2.2/10 quality rating vs BDRX's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Biodexa Pharmaceuticals plc (BDRX) and BGM Group Ltd. (BGM) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BDRX currently trades at $3.47 with a QOC of 1.7/10, while BGM trades at $0.32 with a QOC of 2.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).